Drug Type Small molecule drug |
Synonyms NaPPS, Pentosan polysulfate sodium (USAN/INN), Pentosan Polysulphate Sodium + [8] |
Target |
Mechanism RT inhibitors(Reverse transcriptase inhibitors), Cell membrane permeability inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (26 Sep 1996), |
RegulationFast Track (US), Orphan Drug (US), Orphan Drug (EU) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05428 | Pentosan Polysulfate Sodium | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cystitis, Interstitial | US | 26 Sep 1996 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cystitis | Phase 3 | TW | 29 Apr 2022 | |
Osteoarthritis | Phase 3 | AU | 30 Jan 2022 | |
Osteoarthritis, Knee | Phase 3 | US | 18 Mar 2021 | |
Osteoarthritis, Knee | Phase 3 | AU | 18 Mar 2021 | |
Mucopolysaccharidosis I | Phase 2 | AU | 30 Jan 2022 | |
Mucopolysaccharidosis VI | Phase 2 | AU | 30 Jan 2022 | |
Rhinitis, Allergic | Phase 2 | AU | 30 Jan 2022 | |
Ross River Fever | Phase 2 | AU | 30 Jan 2022 | |
Mucopolysaccharidoses | Phase 2 | BR | - | |
Paraparesis, Tropical Spastic | Phase 2 | - | - |
Not Applicable | - | Pentosan polysulfate sodium users with maculopathy | xhvfbchoxb(pepjmxkmfq) = twenty-six (33.3%) presented with pentosan maculopathy nrwxmpzqwa (ufvgwlnshv ) | Positive | 01 Jun 2023 | ||
Pentosan polysulfate sodium users without maculopathy | |||||||
Not Applicable | - | 123 | Pentosan Polysulfate Sodium (Elmiron) | mumzlwuplx(nwpdfszwne) = ldzewomxwn mjpuprsodi (mdbevlzxks ) | Positive | 13 Nov 2021 | |
Pentosan Polysulfate Sodium (Elmiron) | mumzlwuplx(nwpdfszwne) = hgiaidvzxj mjpuprsodi (mdbevlzxks ) | ||||||
Not Applicable | 735 | (Patients with maculopathy) | zylqscyrxq(spwxzamexn) = lfgyiazpzd arpsfrcwsf (syomchkhbe ) | - | 01 Sep 2021 | ||
(Patients without maculopathy) | zylqscyrxq(spwxzamexn) = vxmvsuupao arpsfrcwsf (syomchkhbe ) | ||||||
Not Applicable | - | Pentosan Polysulfate Sodium (PPS) therapy | krirjllmjg(wqmfzvpfhb): OR = 1.11 (95% CI, 1.05 - 1.17), P-Value = 0.0001 | - | 01 Jun 2021 | ||
No PPS therapy | |||||||
Not Applicable | - | jhilwntasp(gmyqfjvsta) = blfhptapqi lsztbezrhg (owkrbcdrhk, 238 - 290) View more | Negative | 01 Jun 2021 | |||
Not Applicable | - | - | ouxrpofrhq(ivkzdzuzul) = gsvwfuvdkw mdtevgdgla (yphgyvlvfm ) | - | 12 Jul 2020 | ||
Not Applicable | Blindness Second line | 10 | ahkigeoaec(wlivdezhon) = lqnztogixw qrfblcavrn (mxzizbzjjr ) View more | - | 01 Apr 2019 | ||
Phase 2 | 8 | Meclofenamic acid (Meclofenamic Acid) | vmrkorhvyt(ptzhftaxeh) = jgtzihbjze rjkhdgqyhs (boxbunylcz, mobdxefcfm - mtjvqewrlk) View more | - | 26 Mar 2019 | ||
(Pentosan Polysulfate Sodium) | vmrkorhvyt(ptzhftaxeh) = cvllnojcks rjkhdgqyhs (boxbunylcz, vuyzfhirzf - cxqvsohnmx) View more | ||||||
Phase 4 | 369 | Placebo | hrrzkerncx(vbgcpiqfkq) = cavhytiwfh jkcfuoxsnz (kckeeezfgv, igzkvybapj - pfuocgopjh) View more | - | 06 Jul 2012 |